---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-002925"
form_type: "8-K"
ticker: "OCGN"
cik: "0001372299"
company_name: "Ocugen, Inc."
filed_at: "2025-01-29T23:59:59+00:00"
generated_at: "2026-05-27T06:37:36.509175+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# Ocugen posts corporate presentation showing positive retinal gene therapy data

## Summary
- Mean change in total atrophy area: treated 0.12±0.36 mm2 vs untreated 0.73±0.26 mm2 (84% less progression).
- LL VA decline at 6 months was lower in treated eyes compared to untreated across multiple study cohorts.
- Presentation features data from cohorts 006-001, 007-001, and 006-004 suggesting consistent treatment benefit.
- Ocugen plans to use this presentation in discussions with investors and analysts on January 29, 2025.

## SEC filing metadata
- accession: 0001628280-25-002925
- form_type: 8-K
- ticker: OCGN
- cik: 0001372299
- company_name: Ocugen, Inc.
- filed_at: 2025-01-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372299/000162828025002925/0001628280-25-002925-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372299/000162828025002925/ocgn-20250129.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-002925
- JSON: https://secwatch.observer/filing/0001628280-25-002925.json
- Plain text: https://secwatch.observer/filing/0001628280-25-002925.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.